Ten-year incidence and assessment of safe screening intervals for diabetic retinopathy: the OPHDIAT study.

Chloé Chamard Vincent DaienAli ErginayJean-Francois GautierMax VillainRamin TadayoniIsabelle CarrierePascale Massin

Published in: The British journal of ophthalmology (2020)

These data suggest that in Paris area, a 2-year, 3-year and 4-year screening interval was considered safe for type 1 DM, type 2 DM and for low-risk patients with type 2 DM, respectively, without DR at the first examination. While these data might be used to support the consideration of extending screening intervals, a randomised clinical trial would be suitable to confirm the safety for patients with DM.

Keyphrases

diabetic retinopathy
clinical trial
electronic health record
open label
glycemic control
study protocol
optical coherence tomography
double blind
risk factors
type diabetes
randomized controlled trial
machine learning
weight loss
skeletal muscle
data analysis
editorial comment